Integral Health Asset Management, LLC
CIK 1773206 · EDGAR ↗
- sum of disclosed values for 2026-03-31; 0 positions have no disclosed value and are left out of the sum, counted here rather than dropped
- $2.1B
- every reported holding for this filer and quarter, including ones with no disclosed value
- 90
- positions with no comparable holding in the prior quarter (kind new), 2026-03-31
- 30
- positions absent from this quarter's filing after being held last quarter (kind exit), 2026-03-31 — inferred from absence, not a sale record
- 26
Quarter-end snapshot, filed up to 45 days later — not current holdings. What a 13F covers ↓
Changes · Quarter ended 2026-03-31. Newest filing in this build: 2026-07-31. Per-row filing dates are on each receipt.
by shares · How classified ↗Period
| The reviewed ticker for the filed issuer name and share class, the same mapping the Reported positions table uses. Symbols are never inferred from names; — means no reviewed mapping. | position matched across quarters by exact reported CUSIP over a registry gap — never a name match | NEW / ADD / TRIM / EXIT by share count · NO CHANGE = same shares; the value moved with price, so never an ADD or a TRIM · EXIT = absent this quarter (disposed, delisted, confidential, or reported by an affiliate) — the filing does not say which · NO PRIOR = no comparable prior quarter on record (a first filing, or a quarter filed inside an affiliate's report), so not called a new stake · n/c = not classifiable: value undisclosed on one side of the pair, or neither shares nor value can classify it · †v: the reported share count is unchanged across the pair; this build's data classified the change from its reported value; builds from 2026-09-10 on read it as NO CHANGE | derived by Public Filings from the published data; “no value” means the source did not disclose a usable value — never zero | Prev value | Curr value | Prev shares | Curr shares | |
|---|---|---|---|---|---|---|---|---|
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM PAR $.01 · position key pos:14207 · issuer key iss:973 | ADD | +$27.7M | +250,000 | $218M | $245M | 1,250,000 | 1,500,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:14656 · issuer key iss:1552 | ADD | +$50.3M | +300,000 | $95.6M | $146M | 1,200,000 | 1,500,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM NEW · position key pos:12465 · issuer key iss:548 | ADD | +$16.5M | +200,000 | $89.0M | $105M | 1,400,000 | 1,600,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:14656 · issuer key iss:1552 PUT | NEW | +$72.9M | +750,000 | $0 | $72.9M | — | 750,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM NEW · position key pos:12465 · issuer key iss:548 CALL | ADD | +$34.1M | +500,000 | $31.8M | $65.9M | 500,000 | 1,000,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:15140 · issuer key iss:1537 | TRIM | −$15.4M | −20,000 | $81.0M | $65.7M | 105,000 | 85,000 |
| — | share class as filed: CL A · position key sid:sec:prov:c6f0567aff349dfe2dab4a6ee5ba8988 · issuer key cusip6:92337R | TRIM | −$26.8M | −200,000 | $91.2M | $64.4M | 1,800,000 | 1,600,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:15318 · issuer key iss:392 | ADD | +$16.0M | +70,000 | $41.1M | $57.1M | 200,000 | 270,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: SHS · position key pos:17657 · issuer key iss:2200 | ADD | +$37.0M | +1,150,000 | $18.4M | $55.4M | 850,000 | 2,000,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:18251 · issuer key iss:315 | ADD | +$25.2M | +500,000 | $28.1M | $53.3M | 750,000 | 1,250,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:16702 · issuer key iss:1556 | ADD | +$1.3M | +125,000 | $50.8M | $52.2M | 475,000 | 600,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:17751 · issuer key iss:1214 | ADD | +$24.8M | +175,000 | $26.3M | $51.1M | 250,000 | 425,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:11808 · issuer key iss:635 | ADD | +$13.2M | +100,000 | $37.2M | $50.4M | 1,500,000 | 1,600,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: ORD · position key pos:17695 · issuer key iss:2037 | NEW | +$49.3M | +250,000 | $0 | $49.3M | — | 250,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:14656 · issuer key iss:1552 CALL | NEW | +$48.6M | +500,000 | $0 | $48.6M | — | 500,000 |
| — | share class as filed: COM · position key pos:12603 · issuer key iss:74 | ADD | +$1.9M | +375,000 | $43.5M | $45.4M | 2,200,000 | 2,575,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:14095 · issuer key iss:307 | ADD | +$13.1M | +325,000 | $21.5M | $34.5M | 225,000 | 550,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:15121 · issuer key iss:1122 | ADD | +$6.3M | +1,300,000 | $21.1M | $27.4M | 3,000,000 | 4,300,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: SPONSORED ADR · position key pos:15965 · issuer key iss:175 | ADD | +$7.1M | +25,000 | $19.2M | $26.3M | 90,000 | 115,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:17712 · issuer key iss:1630 | ADD | +$11.4M | +200,000 | $13.2M | $24.6M | 300,000 | 500,000 |
Flags: no row carries a flag.
1–20 of the 100 changes on this page
1–100 of 104 changes
Mark-to-market only (no share change) · 12
Positions whose share count is identical in both quarters; the value changed with price, not with a decision.
| The reviewed ticker for the filed issuer name and share class, the same mapping the Reported positions table uses. Symbols are never inferred from names; — means no reviewed mapping. | position matched across quarters by exact reported CUSIP over a registry gap — never a name match | NEW / ADD / TRIM / EXIT by share count · NO CHANGE = same shares; the value moved with price, so never an ADD or a TRIM · EXIT = absent this quarter (disposed, delisted, confidential, or reported by an affiliate) — the filing does not say which · NO PRIOR = no comparable prior quarter on record (a first filing, or a quarter filed inside an affiliate's report), so not called a new stake · n/c = not classifiable: value undisclosed on one side of the pair, or neither shares nor value can classify it · †v: the reported share count is unchanged across the pair; this build's data classified the change from its reported value; builds from 2026-09-10 on read it as NO CHANGE | derived by Public Filings from the published data; “no value” means the source did not disclose a usable value — never zero | Prev value | Curr value | Prev shares | Curr shares | |
|---|---|---|---|---|---|---|---|---|
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: SPONSORED ADR · position key pos:14360 · issuer key iss:1327 | NO CHANGE | +$3.7M | 0 | $34.5M | $38.2M | 250,000 | 250,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:12687 · issuer key iss:419 | NO CHANGE | −$5.5M | 0 | $26.7M | $21.3M | 650,000 | 650,000 |
| — | share class as filed: COM · position key sid:sec:prov:d00159df48fd34cc806ae902a076ba0a · issuer key cusip6:603170 | NO CHANGE | −$6.9M | 0 | $27.2M | $20.3M | 750,000 | 750,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:11462 · issuer key iss:1296 | NO CHANGE | −$1.5M | 0 | $21.3M | $19.8M | 150,000 | 150,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: SHS · position key pos:11075 · issuer key iss:2299 | NO CHANGE | −$6.8M | 0 | $21.5M | $14.7M | 900,000 | 900,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:10610 · issuer key iss:1761 | NO CHANGE | −$2.3M | 0 | $16.4M | $14.0M | 200,000 | 200,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM NEW · position key pos:11142 · issuer key iss:1475 | NO CHANGE | +$1.1M | 0 | $11.8M | $12.9M | 40,000 | 40,000 |
| — | share class as filed: COM · position key sid:sec:prov:9c654c0b85e21e330a7ebfd2ced217c7 · issuer key cusip6:834203 | NO CHANGE | −$4.2M | 0 | $15.0M | $10.9M | 325,000 | 325,000 |
| a reviewed mapping row for this filed issuer name and share class (never inferred from the name) | share class as filed: COM · position key pos:10390 · issuer key iss:416 | NO CHANGE | +$1.2M | 0 | $8.0M | $9.1M | 80,000 | 80,000 |
| — | share class as filed: COM NEW · position key sid:sec:prov:cb2ee571f458a0a64c1c152656def847 · issuer key cusip6:76200L | NO CHANGE | +$1.4M | 0 | $4.7M | $6.1M | 2,000,000 | 2,000,000 |
| — | share class as filed: COM · position key pos:15345 · issuer key iss:1204 | NO CHANGE | −$1.2M | 0 | $4.1M | $3.0M | 100,000 | 100,000 |
| — | share class as filed: COM NEW · position key sid:sec:prov:9e958f4e10d0d474cc9e75d42ea33a9a · issuer key cusip6:88032L | NO CHANGE | +$635K | 0 | $2.0M | $2.7M | 167,000 | 167,000 |
Flags: no row carries a flag.
Holdings without a security ID are counted, not compared. Method ↗
Reported positions — 2026-03-31
86 issuers · 90 rowsViewThis build carries one quarter for this manager: 2026-03-31. Notable managers carry four published quarters, others two.
| This list carries reported issuer names and security identities, without a dated ticker mapping. Symbols are not inferred from names. | a position composed from a base filing plus NEW-HOLDINGS amendments keeps every source row here; the composition's latest filed date is the one shown served from this build's published holdings (derived from the filer's own reported rows); every row resolves to its filing | Share of total reported value, calculated only when the full position list has disclosed values. This is 13F long value, not total assets. | value undisclosed on the filing: retained and counted, excluded from sums, never shown as $0 | Shares | Wt | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REVOLUTION MEDICINES INC3 positions · 3 reported rows
| $267M | 2,750,000 | 12.8% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INSMED INC · COM PAR $.01 CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $245M | 1,500,000 | 11.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CYTOKINETICS INC | $171M | 2,600,000 | 8.2% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | REGENERON PHARMACEUTICALS · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $65.7M | 85,000 | 3.1% | ||||||||||
| — | VERA THERAPEUTICS INC · CL A CUSIP 92337R101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $64.4M | 1,600,000 | 3.1% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CARDINAL HEALTH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $57.1M | 270,000 | 2.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ROIVANT SCIENCES LTD · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $55.4M | 2,000,000 | 2.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIGHTSPRING HEALTH SVCS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $53.3M | 1,250,000 | 2.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | RHYTHM PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $52.2M | 600,000 | 2.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MERCK & CO INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $51.1M | 425,000 | 2.4% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDGEWISE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $50.4M | 1,600,000 | 2.4% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ASTRAZENECA PLC · ORD CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $49.3M | 250,000 | 2.4% | ||||||||||
| — | ALIGNMENT HEALTHCARE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $45.4M | 2,575,000 | 2.2% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NOVARTIS AG · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $38.2M | 250,000 | 1.8% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BOSTON SCIENTIFIC CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $34.5M | 550,000 | 1.7% | ||||||||||
| — | MINERALYS THERAPEUTICS INC2 positions · 2 reported rows
| $33.9M | 1,250,000 | 1.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LIFESTANCE HEALTH GROUP INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $27.4M | 4,300,000 | 1.3% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ASCENDIS PHARMA A/S · SPONSORED ADR CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $26.3M | 115,000 | 1.3% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SCHOLAR ROCK HLDG CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $24.6M | 500,000 | 1.2% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELEVANCE HEALTH INC FORMERLY · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $22.0M | 75,000 | 1.1% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CENTENE CORP DEL · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $21.3M | 650,000 | 1.0% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BRIDGEBIO PHARMA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $20.4M | 275,000 | 1.0% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | NEUROCRINE BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $19.8M | 150,000 | 0.9% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GLAUKOS CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.8M | 175,000 | 0.9% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ARROWHEAD PHARMACEUTICALS IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $18.8M | 300,000 | 0.9% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VERTEX PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.9M | 40,000 | 0.9% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ORIC PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.7M | 1,400,000 | 0.8% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ALUMIS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $17.6M | 800,000 | 0.8% | ||||||||||
| — | FRESENIUS MEDICAL CARE AG · SPONSORED ADR CUSIP 358029106 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $17.5M | 775,000 | 0.8% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | INTUITIVE SURGICAL INC · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $16.1M | 35,000 | 0.8% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | UNIQURE NV · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.7M | 900,000 | 0.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TARSUS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $14.0M | 200,000 | 0.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | GILEAD SCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.9M | 100,000 | 0.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELI LILLY & CO · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.8M | 15,000 | 0.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | EDWARDS LIFESCIENCES CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.6M | 170,000 | 0.7% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COGENT BIOSCIENCES INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.5M | 350,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ELANCO ANIMAL HEALTH INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.2M | 550,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | MADRIGAL PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $13.1M | 25,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PRAXIS PRECISION MEDICINES I · COM NEW CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.9M | 40,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DIANTHUS THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $12.6M | 150,000 | 0.6% | ||||||||||
| — | REGENXBIO INC · COM CUSIP 75901B107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $12.6M | 1,500,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | QUEST DIAGNOSTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.8M | 60,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | XENON PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.6M | 200,000 | 0.6% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ERASCA INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.3M | 700,000 | 0.5% | ||||||||||
| — | ALTO NEUROSCIENCE INC · COM SHS CUSIP 02157Q109 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $11.2M | 500,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | BIOGEN INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.0M | 60,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DEXCOM INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $11.0M | 175,000 | 0.5% | ||||||||||
| — | SOLENO THERAPEUTICS INC · COM CUSIP 834203309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $10.9M | 325,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DISC MEDICINE INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.9M | 170,000 | 0.5% | ||||||||||
| — | NURIX THERAPEUTICS INC · COM CUSIP 67080M103 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $10.9M | 700,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CVS HEALTH CORP · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.8M | 150,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | COOPER COS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $10.7M | 150,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | THERMO FISHER SCIENTIFIC INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.8M | 20,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LIVANOVA PLC · SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.5M | 150,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | LANTHEUS HLDGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.5M | 125,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | TANGO THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.4M | 450,000 | 0.5% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IONIS PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.4M | 125,000 | 0.4% | ||||||||||
| — | SANA BIOTECHNOLOGY INC · COM CUSIP 799566104 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $9.2M | 3,200,000 | 0.4% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | CELCUITY INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $9.1M | 80,000 | 0.4% | ||||||||||
| — | PROTARA THERAPEUTICS INC · COM STK CUSIP 74365U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $9.1M | 1,750,000 | 0.4% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ENVISTA HOLDINGS CORPORATION · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.9M | 350,000 | 0.4% | ||||||||||
| — | BIOHAVEN LTD · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $8.5M | 1,000,000 | 0.4% | ||||||||||
| — | SYNDAX PHARMACEUTICALS INC · COM CUSIP 87164F105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $8.2M | 350,000 | 0.4% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | VIKING THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $8.1M | 250,000 | 0.4% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | DEFINIUM THERAPEUTICS INC · COM SHS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $7.6M | 400,000 | 0.4% | ||||||||||
| — | BEAM THERAPEUTICS INC · COM CUSIP 07373V105 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $7.1M | 300,000 | 0.3% | ||||||||||
| — | REZOLUTE INC · COM NEW CUSIP 76200L309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $6.1M | 2,000,000 | 0.3% | ||||||||||
| — | CAPRICOR THERAPEUTICS INC · COM NEW CUSIP 14070B309 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $6.1M | 200,000 | 0.3% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IQVIA HLDGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $6.0M | 35,000 | 0.3% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | AXSOME THERAPEUTICS INC. · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.9M | 35,000 | 0.3% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | PROTAGONIST THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $5.3M | 50,000 | 0.3% | ||||||||||
| — | EVOMMUNE INC · COM SHS CUSIP 30054Y107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $5.2M | 225,000 | 0.2% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ACADIA HEALTHCARE COMPANY IN · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.7M | 200,000 | 0.2% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | ZIMMER BIOMET HOLDINGS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $4.5M | 50,000 | 0.2% | ||||||||||
| — | FORTE BIOSCIENCES INC · COM NEW CUSIP 34962G208 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $3.9M | 150,000 | 0.2% | ||||||||||
| — | LB PHARMACEUTICALS INC · COM SHS CUSIP 50180M108 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $3.7M | 150,000 | 0.2% | ||||||||||
| — | SAVARA INC · COM CUSIP 805111101 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $3.3M | 600,000 | 0.2% | ||||||||||
| — | RELMADA THERAPEUTICS INC · COM CUSIP 75955J402 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $3.1M | 450,000 | 0.1% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | IMMUNOCORE HLDGS PLC · ADS CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $3.0M | 100,000 | 0.1% | ||||||||||
| — | MAZE THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $3.0M | 100,000 | 0.1% | ||||||||||
| — | TENAX THERAPEUTICS INC · COM NEW CUSIP 88032L605 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $2.7M | 167,000 | 0.1% | ||||||||||
| — | INHIBIKASE THERAPEUTICS INC · COM NEW CUSIP 45719W205 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $2.3M | 1,350,000 | 0.1% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | OLEMA PHARMACEUTICALS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.2M | 150,000 | 0.1% | ||||||||||
| — | INVENTIVA SA · ADS CUSIP 46124U107 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $2.2M | 400,000 | 0.1% | ||||||||||
| verified against the SEC company list on 2026-09-10 — a reviewed mapping row for this filed issuer name and class (never inferred) | SIONNA THERAPEUTICS INC · COM CUSIP — quarter ended 2026-03-31 filed filed 2026-05-15 +45d | $2.0M | 50,000 | 0.1% | ||||||||||
| — | UNICYCIVE THERAPEUTICS INC · COM NEW CUSIP 90466Y202 quarter ended 2026-03-31 filed filed 2026-05-15 +45d ticker not yet mapped | $1.5M | 225,000 | 0.1% |
1–20 of 86 issuers
1–86 of 86 issuers · page 1 of 1
One line per issuer, largest first — open a line for its reported rows. Grouping ↗
Book shape
Tick = median of the 8,748 tracked filers with a 2026-03-31 book (the index median: the 8,662 with a complete book). Concentration uses reported 13F long value, not total assets; the index is withheld when any position lacks a value.- 70.0%below median 80.0%
- integer Herfindahl–Hirschman index in basis points over disclosed position values
- 339 bpsbelow median 446 bps
- holdings with no disclosed value (undisclosed, or unreadable on the filing) — kept and counted, never shown as zero
- 90 / 90median book 97.5 positions
116 quarter-over-quarter rows
Filing history
| Period | Source |
|---|---|
| 2026-03-31 | EDGAR ↗ |
Complete source filings on SEC EDGAR
The filing on EDGAR is the record, including any filed after this build.
Open Integral Health Asset Management, LLC's 13F filings on SEC EDGAR ↗A 13F is a quarterly, long-only snapshot filed up to 45 days late — not current holdings. what a 13F covers ↗
13F reports cover LONG positions in Section 13(f) securities (US exchange-traded equities plus reportable options, warrants, certain convertibles) held by managers with at least $100M in such securities — so managers below that threshold are absent entirely. No short positions, no cash, no non-13(f) assets — not a full portfolio, and not a census of institutional ownership.
Positions are quarter-end snapshots filed up to 45 days late — not current holdings: a position may have changed or closed since the quarter ended.
Values are the manager's stated market value at quarter-end in era-dependent units (whole dollars for form versions effective 2023-01-03 onward, thousands before), normalized here to whole dollars; each record notes its original unit.
Affiliated managers may report the same position, so one position can appear under more than one filer.
Positions under confidential treatment may be omitted until a later amendment discloses them.
These are disclosures, not investment advice.